|
BioPharma Credit PLC - Winchester, England-based life sciences debt investment trust - Says that together with BioPharma Credit Investments V it has entered into a second amendment and waiver with Akebia Therapeutics Inc. This amends and waives certain provisions of the $100 million loan agreement dated November 11, 2019. As a result of this amendment Akebia has made a $25 million prepayment, reducing the outstanding balance to $75 million. Akebia will make payments on the remaining balance as originally agreed, starting in September. The loan balance is expected to be $27 million by January 2024.
The company adds that its share of the prepayment will be $12.5 million, and its share of the remaining balance will be $37.5 million.
Current stock price: $0.97, up 2.1% in London on Wednesday
12-month change: up 1.0%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
